NCT00885872 - Rosuvastatin Evaluation of Atherosclerotic Chinese Patients (REACH) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2009

Primary Completion Date

March 31, 2012

Study Completion Date

March 31, 2012

Conditions

HyperlipidemiaAtherosclerosis

Interventions

DRUG

Rosuvastatin (Crestor)

at visit 2 each eligible subject will be allocated to rosuvastatin. study medication wil be taken orally with water once daily, as directed by the study physician. subjects who meet the criteria at visit 3, dosage of rosuvastatin will be titrated.

Trial Locations (1)

100000

RECRUITING

Chinese PLA General Hospital, Beijing